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Patients’ Expectations of the Benefits and Harms
of Treatments, Screening, and Tests
A Systematic Review
Tammy C. Hoffmann, PhD; Chris Del Mar, MD, FRACGP
IMPORTANCE Unrealistic patient expectations of the benefits and harms of interventions can
influence decisionmaking andmay be contributing to increasing intervention uptake and
health care costs.
OBJECTIVE To systematically review all studies that have quantitatively assessed patients’
expectations of the benefits and/or harms of any treatment, test, or screening test.
EVIDENCE REVIEW A comprehensive search strategy was used in 4 databases (MEDLINE,
Embase, Cumulative Index to Nursing and Allied Health Literature, PsycINFO) up to June
2013, with no language or study type restriction. We also ran cited reference searches of
included studies and contacted experts and study authors. Two researchers independently
evaluatedmethodological quality and extracted participants’ estimates of benefit and harms
and authors’ contemporaneous estimates.
FINDINGS Of the 15 343 records screened, 36 articles (from 35 studies) involving a total of
27 323 patients were eligible. Fourteen studies focused on a screen, 15 on treatment, 3 a test,
and 3 on treatment and screening. More studies assessed only benefit expectations (22
[63%]) than benefit and harm expectations (10 [29%]) or only harm (3 [8%]). Fifty-four
outcomes (across 32 studies) assessed benefit expectations: of the 34 outcomes with
overestimation data available, the majority of participants overestimated benefit for 22
(65%) of them. For 17 benefit expectation outcomes, we could not calculate the proportion
of participants who overestimated or underestimated, although for 15 (88%) of these, study
authors concluded that participants overestimated benefits. Expectations of harmwere
assessed by 27 outcomes (across 13 studies): underestimation data were available for 15
outcomes and themajority of participants underestimated harm for 10 (67%) of these. A
correct estimation by at least 50% of participants only occurred for 2 outcomes about benefit
expectations and 2 outcomes about harm expectations.
CONCLUSIONS AND RELEVANCE Themajority of participants overestimated intervention
benefit and underestimated harm. Clinicians should discuss accurate and balanced
information about intervention benefits and harms with patients, providing the opportunity
to develop realistic expectations andmake informed decisions.
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T heuptakeofmedical interventions (treatments, tests, andscreening) is ever increasing and cost more than $2.5 tril-lion,ornearly 18%oftheUSgrossnationalproduct, in2010.1
Theoveruseofmanymedical interventions is recognized2yetpoorly
documented and therefore almost certainlymore prevalent than is
realized.3 It is compounded by overdiagnosis of many conditions.4
This drives up the costs of health care unnecessarily, putting strain
on,and increasinganxietiesabout, thesustainabilityof currentmod-
els of care. It may also unnecessarily harm patients—“overtreat-
ment” implying anunfavorablebenefit-to-harmratiobecausemost
screens, tests, andtreatmentshavesomeharms,andthesemayout-
weigh the benefits.4,5 Overdiagnosis can harm patients in a num-
ber of ways, including the potential for emotional distress caused
bythedisease label itself,6,7aswellas theresultantunnecessarytreat-
ment, with associated risks and costs, of latent disease that might
never otherwise have caused symptoms or early death.4
Why medical interventions are overused is unclear, but sug-
gested factors include the preferences and expectations of health
careusers,8patient assumptions thatmore tests and treatments in-
dicate superior care, payment systems that favor providing an in-
tervention over talking with patients, defensive medicine, and the
efficiencyappeal oforderinga testorprescriptionover the timeand
skills requiredtoexplainwhy itmaynotbeneeded.5Currentdecision-
making practices have acknowledged inadequacies,9 and improv-
ing patients’ involvement in making truly informed health deci-
sions may improve the appropriate use of interventions.
Balancing the concerns about the overuse of interventions, at
theotherendof thespectrum, isunderuse. Interventionswithstrong
evidenceof overall benefit can improvehealthoutcomesonly if pa-
tients commenceandcontinuewith them.Pooradherence tomedi-
cal recommendations, particularlymedicationuse, hasbeenwidely
studied, with factors such as poor communication of intervention
information contributing to it.10 Underestimating the benefits and
overestimating the harms of interventions may contribute to poor
adherence to effective interventions.
Reportsof individuals’ (eitherpatientsor thegeneral public) ex-
pectations about the likely benefit or harmof various interventions
are fragmentedacross the literature.Weaimed to systematically re-
view all studies that had quantitatively measured patient or public
expectations of the benefit and/or harmof anymedical treatment,
test, or screen.
Methods
Types of Studies, Participants, and OutcomeMeasures
All quantitative primary study designs were eligible. We had no re-
strictionsaboutparticipanteligibility. Participants could,butdidnot
need to, be planning to receive the intervention being studied.
We included studies in which participants were asked to pro-
vide aquantitative estimate of the expectedbenefits and/or harms
of a treatment, test, or screen (a test conducted in people without
disease signs or symptoms). Outcomes were eligible if they asked
about the chance of the benefit or harm occurring and/or the size
of it. Studies inwhich participantswere asked to provide a descrip-
tive estimatewithout any quantification (eg, “muchbetter,” “a little
worse”) and those that only measured expectations about the risk
of having or developing a disease or condition were excluded.
SearchMethods for Identification of Studies
Weused a comprehensive search strategy consisting of a combina-
tion of subject heading terms, free text words, and wild cards and
proximity operators to broaden search retrieval and searched
MEDLINE (1946 through June 2013), Embase (1974 through June
2013),Cumulative IndextoNursingandAlliedHealthLiterature (1981
through June 2013), and PsycINFO (1967 through June 2013). We
developed the strategy in consultation with a medical librarian ex-
perienced in systematic reviews. Initial search terms were drawn
fromasmall setof keyarticles.Weusedan iterativeprocessofbuild-
ing a search strategy, running the search, scanning the relevant re-
trieved articles for additional terms, and then rebuilding the search
strategy with the newly identified relevant terms and related sub-
ject headings. The final search strategy forMEDLINE (eAppendix in
the Supplement) was adapted for each database. To identify addi-
tional published, unpublished, and ongoing studies, we (1) tracked
relevant references throughWebofScience’s cited referencesearch,
(2) scanned the reference lists of identified studies, (3) contacted
experts and researchers in the field, and (4) posted a request to the
international evidence-based health care listserv.
Study Selection
A reviewauthor (T.C.H.) anda researchassistant screened the titles
andabstractsofarticles identified in thesearchesandbyothermeth-
ods and eliminated articles according to the inclusion criteria. We
obtained the full texts of studies considered eligible from this pro-
cess or for which eligibility was unclear. A research assistant and 1
author (T.C.H.) independently decided each trial’s inclusion or ex-
clusion. We resolved any disagreements by discussion, and when
consensuscouldnotbe reached, theother author (C.D.M.)wascon-
sulted and a decisionmade.
Data Extraction and Assessment
ofMethodological Quality
Both of us (T.C.H., C.D.M.) independently completed a data extrac-
tion form to extract data and record the methodological quality of
studies. Disagreements were resolved by discussion. Most in-
cluded studies were a survey, and accordingly we extracted infor-
mation relevant to key quality criteria for assessment of bias in sur-
veys, namely, clear research question, sufficiently large and
representative samplingmethod,outcomemeasuresand/or instru-
ments used, and response rate (ideally60%)11 (Tables 1 and 2).
Weextracteddata for theoutcomesand/ormeasures relevant to the
review’s purpose. For intervention studies (usually providing par-
ticipants with information about the intervention being exam-
ined),weonly includedbaseline data or, if a controlled trial, control
group data. Where the authors of studies had provided a contem-
poraneous estimate of the benefits or harms of the intervention(s)
and published this as the “correct” answer, we extracted this. For a
number of studies, we contacted authors for additional data or to
clarify study details.
Data Analysis
For studies that provided a correct answer about an intervention’s
benefits or harms, where possible, we extracted or calculated the
proportionofparticipantswho respondedcorrectlyorwithanover-
estimationorunderestimation.Ameta-analysiswasnotpossiblebe-
cause of the range of study designs and outcomes used.
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Table 1. Details of Studies That Assessed Participants’ Benefit and Harm Expectations of Treatment
Source
Study Purpose/
Method of
Data Collection Participants
Outcomes and/or Measures Relevant
to Systematic Review Purpose Authors’ Conclusions
Baars et al,12
2009
To assess patients’
perspective about benefit
and risk of infliximab use/
Written survey, completed
at clinic
152 patients (mean age,
38 y; 61% women) attending
an inflammatory bowel
disease outpatient clinic in
the Netherlands (all patients
invited during recruitment
period)
Benefits of infliximab: remission rate after
1. 2 wk;
2. 1 y
Risks of infliximab use compared with the general
population:
3. risk of lymphoma compared to general
population
4. risk of dying from a serious adverse effect
The majority of patients
overestimated remission
rates and
underestimated risks of
infliximab use
Bernstein
et al,13
2012
To assess pregnant women’s
estimates of the risks and
benefits of trial of labor after
previous cesarean delivery/
Face-to-face survey
155 women admitted for
delivery who were eligible for
trial of labor after 1 previous
cesarean delivery (87 for trial
of labor; 68 who elected for
repeat cesarean delivery) in
1 hospital in the US
1. Chance of success of trial of labor after previous
cesarean delivery
2. Risk of uterine rupture during vaginal delivery
Women who are
candidates for trial of
labor after a previous
cesarean delivery appear
to know little about the
risks and benefits of this
mode of delivery
Coo et al,14
2001
To assess women’s
knowledge of HT/
Telephone survey
207 (75% response rate)
female patients aged 45-64 y
from 2 primary care practices
in Canada
1. (Women at increased risk of heart disease) and
2. (women not at increased risk) How many of the
71 women would be protected against heart
disease because they took HT?
3. (women at increased risk for osteoporosis) and
4. (women not at increased risk) How many of the
36 women would not break a hip because they
took HT?
5. (women at increased breast cancer risk) and
6. (women not at increased risk) How many more
women out of 100 would develop breast cancer
because they took HT?
Many women
overestimated the
benefits of HT for hip
fracture reduction and
the potential increase of
lifetime risk of breast
cancer
Fagerlin et al,15
2010a and
Hoffman et al,16
2010a
To determine adults’
knowledge about
information relevant to
medication, screening, or
surgery decisions they
recently made
(DECISIONS study)/
Telephone survey
2575 adults (39% male;
weighted response rate of
51.6%) recruited for a
random-digit dial survey of
English-speaking US adults
≥40 y. Answered specific
Q modules if they had
undergone the particular
treatment, screening, or
surgery or discussed doing so
with a health professional in
the previous 2 y.
Hoffman et al16 present
analysis of responses to
cancer screening modules,
for participants ≥50 y
(n = 1082)—Qs 9 and 10 in
this article
Out of 100 people who have __, about how many
will have
1. knee/hip replacement, pain relief after surgery
2. lower back pain, benefit from back surgery
3. cataract surgery, improved vision
4. hip/knee replacement, complications
5. back surgery, complications
6. back surgery, same or worse pain after surgery
7. cataract surgery, still have to wear glasses after
operation
8. cataract surgery, need a second procedure
9. How often does a high prostate specific antigen
and 10. positive mammogram result in a cancer
diagnosis?
Patient knowledge of
key facts relevant to
recently made medical
decisions is often poor
(Fagerlin et al15).
Participants
overestimated the
positive predictive
values of PSA tests and
mammography
(Hoffman et al16)
Habib et al,17
2008
To explore benefit and risk
perceptions of patients
undergoing peripheral
angioplasty and trial new
information tool/
Face-to-face interview by
consenting clinician after
patients informed of
procedure
200 patients undergoing
peripheral angioplasty over a
12-mo period in UK. Mean
age, 69 y; 67% male. Only
half (100) the participants
received the risk assessment
tool.
“What do you think are the chances (percentage)
you will benefit from today’s procedure?”
Patients undergoing
peripheral angioplasty
tend to overestimate its
benefits and
underestimate its risks
Hudson et al,18
2012a
To assess patients’
expectations of benefits of
screening for breast and
bowel cancer and medication
to prevent hip fracture and
cardiovascular disease/
Mailed survey
Convenience sample of 354
patients (36% response rate)
aged 50-70 y registered with
3 general practices in New
Zealand. Mean age, 60 y;
56% male
Of 5000 people aged 50-70 y ___, how many ___:
1. with osteoporosis, hip fractures would be
prevented by taking medication for 10 y to reduce
the risk of this?
2. screened for bowel cancer regularly for 10 y,
deaths due to bowel cancer would be prevented by
this screening?
3. given medication for 10 y to reduce risk of death
from cardiovascular disease, how many deaths due
to this prevented?
4. [women] screened for breast cancer regularly for
10 y, deaths due to breast cancer prevented by
screening?
Patients overestimated
the risk reduction
achieved (overestimated
benefit) with 4 examples
of screening and
preventative
medications
Kee et al,19
1997
To describe cardiac patients’
understanding of coronary
angioplasty benefit/
Face-to-face interview by
research nurse within 24 h
of angiography and
angioplasty consent
150 consecutively recruited
(30 declined participation)
patients undergoing elective
coronary angioplasty at 2
regional cardiology centers in
the UK
Patient estimates of
1. benefit to life expectancy (in years and months)
2. rate of major complications
Patients vastly
overestimated the
capacity of angioplasty
to control their disease
(continued)
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Table 1. Details of Studies That Assessed Participants’ Benefit and Harm Expectations of Treatment (continued)
Source
Study Purpose/
Method of
Data Collection Participants
Outcomes and/or Measures Relevant
to Systematic Review Purpose Authors’ Conclusions
Lee et al,20
2001
To measure patients’ and
physicians’ expectations
before stem cell transplant
and correlate them with
actual outcomes after
transplant (only patients’
data reported here)/
Mailed survey before
transplant
313 patients (458 invited;
68% response rate) attending
a tertiary care transplant
center in the US and planning
for autologous or allogeneic
hematopoietic stem cell
transplantation for
hematologic disease within 3
mo (but not <1 wk) of study
enrolment (median age, 47 y;
52% male)
1. “What do you think is your chance of being
cured (a) with and (b) without a stem cell
transplant?”
2. “What % of people do you think die during the
transplant hospitalization or from complications
within the first year?”
(6 response options: almost all [>90%], most
[75%-90%], majority [50%-74%], less than half
[25%-49%], few [10%-24%], almost none [<10%])
Patients were fairly
accurate at estimating
mortality when actual
mortality was <30%;
beyond that they had
overly optimistic
expectations.
Patient expectations of
disease-free survival
were high and constant
regardless of disease
stage
Lytsy et al,21
2007
To assess patients’
expectations of the effect of
statins and factors
influencing this/
Postal survey distributed via
pharmacists
829 (69% response rate)
patients presenting a statin
prescription at 1 of 27
pharmacies in Sweden. Mean
age, 65 y; 54% male
“Imagine that one thousand individuals, with a
similar health status as yours, receive the same
lipid-lowering treatment as you for 5 years. How
many of these patients do you believe would not
suffer a heart attack compared to if they did not
receive treatment?”
Patients overestimated
the general effect of
statins
Mancini
et al,22
2006a
To assess impact of
information booklet on
women’s decisions about
genetic testing for BRCA1/2
mutation (only control group
[not given booklet] data
reported here)/
Survey distributed face-to-
face at clinic and mailed back
Control group n = 263 (87%
response rate) of consecutive
women (mean age, 49 y) with
personal history of breast
cancer and the first in the
family to consider BRCA1/2
analysis; recruited from 11
cancer genetic clinics in
France
1. Estimated proportion of breast cancer detected
in women <40 y old with a genetic predisposition
to breast cancer by annual mammography from
30 y of age
2. Estimated proportion of breast cancer
prevented by preventive mastectomy in women
<40 y old with a genetic predisposition to breast
cancer
3. Estimated proportion of ovarian cancer
prevented by preventive ovariectomy in women
with a genetic predisposition to ovarian cancer
Not specified (authors’
conclusions were about
the effect of the
information booklet)
Metcalfe
et al,23
2002
To compare perceptions of
breast cancer risk in women
who had undergone
prophylactic bilateral
mastectomy/
Mailed survey, with
telephone contact before and
after survey
75 (61% response rate)
women who underwent
bilateral mastectomy in any
Ontario hospital in the
previous decade. Mean
(range) age, 48 (23-70) y.
60 women (80%) provided
responses to risk Qs
Asked to estimate their own lifetime risk of
developing breast cancer before and after they
underwent the prophylactic mastectomy
Women who had
preventative breast
surgery significantly
overestimated their
lifetime risk of
developing breast
cancer (except those
with BRCA1/2 gene
mutations)
Ravdin et al,24
1998
To assess adjuvant
chemotherapy expectations
in women with
nonmetastatic breast cancer/
Mailed survey
2660 breast cancer support
group members in the US
invited, 562 responded and a
final sample of 318 eligible
patients (nonmetastatic
breast cancer and received
adjuvant chemotherapy).
Median age, 49 y
Participants asked to estimate their prognosis with
and without adjuvant therapy.
216 (68%) gave estimates of prognosis
Women in the sample
overestimated the value
of adjuvant therapy
Schonwetter
et al,25
1991
To assess knowledge of CPR
in elderly veterans/
Face-to-face survey by an
interviewer at clinic;
telephone call 1-2 wk later
64 eligible (>74 y) veterans
from an outpatient clinic in
the US. Mean (range) age,
82 (75-95) y
Patients asked to estimate their chance (%) of
1. immediate survival after CPR and 2. survival to
hospital discharge. (Only data from first interview
reported here because patients were given CPR
information before the second interview)
The sample consistently
overestimated the
chance of surviving CPR.
Siegel et al,26
2008
To determine patients’ and
parents’ perceptions of risk
and benefits of infliximab for
IBD/
Written survey completed
prior to a public lecture
about IBD treatment
Convenience sample of
165 patients (or parents of
patients) with IBD at 1 of
2 patient education
symposiums in US.
53% were adult patients
(median age, 46 y); 47% were
parents (median age of
children, 16 y); 68% female
Vignette given and asked, “If 100 similar patients
with Crohn disease had the same symptoms and
were treated with Remicade, how many patients out
of those 100:
1. will improve in 2 wk because of the drug?”
2. will be in complete remission after 1 y of
regularly taking the drug?”
3. Compared to general population, what is the
chance of the 35-year-old developing lymphoma
after taking the drug for 1 y?
4. What is the chance of dying of a side effect of
the drug?
Patients and parents of
patients overestimate
the benefit of infliximab
use and underestimate
the risks
Smith et al,27
2008
To examine benefit
expectations on QOL in
kidney transplant recipients/
Computer-assisted telephone
interview, before and 1 y
after transplant
307 (80% response rate)
patients on a renal transplant
waiting list in the US; 210
completed 1-y posttransplant
interview. Mean age, 48 y;
59% male
Patients asked to rate
1. (Pretransplant) their current QOL (from
0 “worst” to 100 “best imaginable”)
2. (Pretransplant) anticipated QOL1 y after a
successful transplant
3. (1 y after transplant) QOL
Patients substantially
overestimated the
benefits to QOL of a
successful kidney
transplant
Watson et al,28
1997
To investigate opinions of the
elderly about CPR decisions/
Face-to-face semistructured
interview at admission and at
discharge
95 (96% response rate)
eligible elderly patients in
1 hospital in New Zealand
recruited from consecutive
admissions over 5-wk period.
Mean age, 80 y; 63% female
Patients asked what they thought the success rate
of CPR was
Elderly patients wish to
be consulted about CPR.
Patients overestimated
the success rate of CPR
(continued)
Patient Expectations of Treatments and Tests Review Clinical Review& Education
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine February 2015 Volume 175, Number 2 277
Downloaded From: http://archinte.jamanetwork.com/ by a UQ Library User  on 10/12/2015
Copyright 2015 American Medical Association. All rights reserved.
Results
Studies Identified
We screened 15 343 studies (after removing duplicates) and dis-
carded 15 252 after examining title and abstract. Of the remaining
91 full-text articles, 36were eligible for inclusion (Figure 1), from35
studies (2 articles were from the same study15,16).
Description of Studies
Characteristicsof thestudiesareshowninTable1 (studiesabouttreat-
ment) andTable2 (tests andscreens). In theSupplement, there is an
expanded version of these tables (eTable 1 and eTable 2) that con-
tainsparticipants’ responsestothequestionsaboutbenefitandharm
expectations, alongwith the “correct” estimateasprovidedbystudy
authors.Theearliest studywaspublished in 1994,43andthemost re-
cent, in2013.47Studieswerefrom16countries,withthehighestnum-
ber (n = 17) from the United States. Study sample size ranged from
4529 to 10 228.38 Across the 35 studies, a total of 27 323 partici-
pants were involved. Across the 16 studies about treatments, there
wasawide rangeof treatments (18) studied (Table 1),withonly4 (in-
fliximab for inflammatory bowel disease,12,26 cardiopulmonary
resuscitation,25,28 prophylacticmastectomy,22,23 and statins for car-
diovascular disease21,30) examined by more than 1 study. Of the 20
studies about tests or screening, 15were concernedwith cancer.
Fourteen(40%)studies focusedonscreening, 15 (43%)ontreat-
ment, 3 (9%)ona test, and3 (9%)onboth treatmentandscreening.
Morestudiesassessedjustexpectationsofbenefit(22[63%])thanben-
efitandharm(10[29%])or justharm(3[8%]).Acrossallstudies,atotal
of81outcomes relevant to the review’spurposeswereused,with54
outcomes assessing benefit expectations and 27 assessing harmex-
pectations(eFigureintheSupplementshowsthisbyinterventiontopic).
Most studies usedmultiple-choice questions to assess expecta-
tions (69% of outcomes); the remainder asked participants to pro-
vide a quantitative estimate (eg, “out of 1000 people, how many
would…”) without providing response options. The most frequent
studydesignwasasurvey(face-to-face,telephone,ormailed). Insome
studies, data were collected from patients who had received, were
about to receive, or were considering receiving the intervention of
interest.* Inothers,participantsweresampledfrompeoplewhowere
currently attending or had recently attended a health care
facility14,18,25,27,28,33,41,45orfromthegeneralpopulation.31,34-36,38,44,46
The response ratewasat least60%in 17of the27studies forwhich it
couldbedetermined.Three studieswere randomized trials,22,30,40 1
wasanonrandomizedtrial,17and2werebefore-and-afterstudies,25,28
inwhichtheeffectofproviding informationwasbeingevaluated(only
control group or baseline data for the relevant outcomewere used).
Expectations of Benefit
Of the 32 studies that assessed expectations of benefit, 21 (37 out-
comes) compared participants’ responses with the study authors’
“correct” estimates of benefit (Figure 2). The majority (50%) of
participants overestimated benefit for 22 (65%) of the 34 out-
comes for which overestimation data were provided. The propor-
tion of participants who overestimated benefit ranged from 7% to
94%.Amajorityofparticipantsprovidedcorrectestimation foronly
2 outcomes: the proportion of people with improved vision after
cataract surgery15 and cervical smear test accuracy.44 Underesti-
mationof benefit by at least 50%ofparticipants occurred for 1 out-
come (benefit of back surgery on lower back pain).10
Seventeenoutcomes (from15studies) arenot shown inFigure2
because for these, either the study authors did not provide a correct
estimateofbenefitoroutcomesweremeasured inawaythatdidnot
enabletheproportionofpatientswhoprovidedacorrectanswer,over-
estimation, or underestimation to be calculated (eg, a mean esti-
mateofbenefit; seeeTables 1and2 in theSupplement). For 15 (88%)
oftheseoutcomes,studyauthorsprovidedcommentinthearticlethat
participants overestimated the benefit of the intervention(s). For 1
outcome,22 the authors reported that the correct answer was un-
known and drew no conclusion about participants’ responses.
Expectations of Harm
In 11 studies (25outcomes), harmexpectationswerecomparedwith
a “correct” estimate of harm; at least 50%of participants underes-
timated the harm for 10 (67%)12,15,19,26,47 of the 15 outcomes for
which underestimation datawere available (Figure 3). The propor-
tion of participantswho underestimated harm ranged from 18% to
*References 12, 13, 15-17, 19-24, 26, 27, 29, 32, 37, 39, 40, 43, 47
Table 1. Details of Studies That Assessed Participants’ Benefit and Harm Expectations of Treatment (continued)
Source
Study Purpose/
Method of
Data Collection Participants
Outcomes and/or Measures Relevant
to Systematic Review Purpose Authors’ Conclusions
Wee et al,29
2006
To investigate patients’
expectations for bariatric
surgery/
Telephone survey
Convenience sample of 45
patients (60% response rate)
planning bariatric surgery
at 1 hospital in US. Mean age,
43 y; mean BMI, 47;
95% female
Patients estimated
1. the highest and
2. the lowest amount of weight they expected to
lose from bariatric surgery
Patients have unrealistic
weight loss expectations
for bariatric surgery
Weymiller
et al,30
2007
To evaluate a decision aid
about statin drugs on
treatment decision making
(only control group [not
given decision aid] data
reported here)/
Self-administered written
survey, completed straight
after clinic visit
98 (99% response rate)
patients with diabetes
mellitus attending a
metabolic clinic in US.
Control group n = 46
(43 responses to risk
estimation Q), with
mean age, 66 y;
57% female
“If you think of 100 people like you, all of whom
are taking a daily statin (cholesterol pill), how
many do you think will have a heart attack in the
next 10 years?” (5 response options)
Not specified (authors’
conclusions were about
the effect of the decision
aid)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided by height in meters squared); CPR, cardiopulmonary resuscitation;
IBD, inflammatory bowel disease; N/A, not available; Q, question; QOL, quality of life; UK, United Kingdom; US, United States.
a Study included treatment and screening.
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Table 2. Details of Studies That Assessed Participants’ Benefit and Harm Expectations of Tests and Screening
Source
Study Purpose/
Method of Data Collection Participants
Outcomes and/or Measures Relevant
to Systematic Review Purpose Authors’ Conclusions
Barratt et al,31
1999
To investigate women’s
estimates of screening
mammography accuracy
and attitudes about
compensation for missed
cancers/
Telephone interview
115 (64% response rate)
women from a national sample
of women aged 30-69 y
(mean, 46 y) in Australia
Estimate of how many of 100 women with early
breast cancer would have it detected with
screening mammography
Unrealistically high
expectations of the
sensitivity of screening
mammography were
common in this sample of
women
Basama et al,32
2004
To assess women’s
perceptions of the 20-wk
anomaly fetal scan and its
limitations/
Survey completed at the
unit, before the scan
385 (8% of total population
attending over 3 mo) pregnant
women presenting at 2
maternity units in the UK for a
20-wk ultrasound scan
Estimate of the percentage of fetal abnormalities
that can be detected by the scan
There was an
overestimation of the
ability of the 20-wk scan
to detect fetal
abnormalities
Black et al,33
1995
To determine how women
aged 40-50 y perceive
their risk of breast cancer
and effectiveness of
screening/
Mailed survey
145 (73% response rate)
women aged 40-50 y
randomly sampled from 1
university medical center in
the US. All had been billed for
a Papanicolaou test recently
and had not been hospitalized
or visited the center more than
twice in 6 mo
Of 1000 women like you, how many will, in the
next 10 y, die from breast cancer
1. if not screened for it by mammography or
physician’s examination; and 2. if screened for it
by mammography or physician’s examinationa
Many women younger
than 50 y substantially
overestimate their breast
cancer risk and the
effectiveness of screening
Chamot and
Perneger,34
2001
To assess accuracy of
women’s perceptions
about mortality reduction
from mammography
screening/
Mailed survey
895 (72% response rate)
women aged 40-80 y and free
of breast cancer randomly
selected from a population
registry in Switzerland
“Does mammography screening prevent death
from breast cancer in women aged over 50?”
Most women were
uninformed about and
overestimated the efficacy
of mammography
screening
Cockburn et al,35
1995
To estimate the public’s
understanding of
screening and its benefits
and limitations/
Telephone interview
835 participants of a
representative sample of the
English-speaking Australian
population aged 18-70 y;
51% male
Asked about the accuracy (by estimating the
percentage of cases detected) of
1. the Papanicolaou test
2. mammography
The public have
misconceptions about the
purpose of screening and
the accuracy of screening
tests
Domenighetti
et al,36
2003
To assess women’s
understanding of benefits
of mammography
screening/
Computer-assisted
telephone interview
4140 (69% response rate of
those eligible) women aged
≥15 y selected by random
telephone digit dialing in the
UK, US, Italy, and Switzerland
1. To what extent can mammography reduce
breast cancer deaths in women ≥50 y screened
every 2 y for 10 y?
2. How many deaths due to breast cancer can be
prevented among 1000 women aged ≥50 y who
have mammography every 2 y for 10 y?
A high proportion of
women overestimated the
benefits of mammography
screening
Gekas et al,37
1999
To estimate information
needs of pregnant women
during screening for
Down syndrome/
Survey completed by
participants at the clinic
200 women (40% response
rate) from population of
pregnant women attending for
amniocentesis at a university
hospital in France. Women
were younger than 38 y with a
positive serum marker after a
maternal serum screening
“What percentage of miscarriage may be induced
by amniocentesis?”
Many participants
overestimated the risk of
amniocentesis, despite
extensive counseling
Gigerenzer
et al,38
2009
To estimate the public’s
knowledge of the benefits
of screening for breast
and prostate cancer/
Face-to-face computer-
assisted interviews in
participants’ homes
10 228 (60% response rate)
participants of a random
sample, stratified to be
representative of the
populations of 9 European
countries. Age distribution:
14-19 y (8%), 20-29 y (17%),
30-39 y (18%), 40-49 y
(18%), 50-59 y (15%),
60-69 y (12%), ≥70 y (12%)
1. (women only asked) If 1000 women ≥40 y are
screened for breast cancer by mammography every
2 y for 10 y, after 10 y how many fewer women
who had the screening die from breast cancer
compared to those who did not?
2. (men only asked) If 1000 men ≥50 y are
screened for prostate cancer (by PSA test) every
2 y, after 10 y, how many fewer men who had the
screening die from prostate cancer compared to
those who did not?
The vast majority
overestimate the benefits
of mammography and PSA
screening
Groves et al,39
2004
To assess patients’
perceptions of the
benefits and risks of
myocardial perfusion
scintigraphy/
Face-to-face interview
with the physician before
and after investigation
Convenience sample (recruited
over 2-mo period) of 90
patients undergoing thallium-
201 myocardial perfusion
study at a university hospital
in the UK. Mean (range) age,
64 (31-90) y; 56% female
Prior to the procedure, patients were asked about
their chance of benefit (%) from itb
Many patients lack
knowledge of the risks of
myocardial perfusion
scintigraphy
Haakenson
et al,40
2006
To assess impact of
intervention to improve
women’s knowledge of
mammography screening
(only control group data
reported here)/
Mailed survey
248 in the control group
(34% response rate) of a
convenience sample of 648
women scheduled for
mammography within 4 wk at
a clinic in the US. Mean age,
61 y
1. What percentage of deaths from breast cancer
are reduced by mammography?
2. What percentage of women will need to return
for additional mammograms after the screening
mammogram?
3. Of the women who return, what percentage will
need biopsies after the extra mammogram?
4. Of all biopsies, what percentage of
abnormalities detected by mammogram will not be
cancerous?
Not specified (authors’
conclusions were about
the effect of the
information booklet)
(continued)
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97%. There was correct harm estimation by at least 50% of par-
ticipants for only 2 outcomes: the proportion of people who still
need glasses after cataract surgery15 and miscarriage risk from
amniocentesis.37 Overestimation of harm by at least 50% of par-
ticipants occurred for only 1 outcome (increased breast cancer
risk from hormone therapy in healthy women).14
Expectations Summarized by Intervention Topic
Cancer—Screening
Fifteenstudies (29outcomes)examinedcancer screening—breast,†
cervical,35,44,45 prostate,16,38 and bowel.18 Most (23 [79%]) out-
comes assessed benefit expectations, with the proportion of par-
†References 16, 18, 22, 31, 33-36, 38, 40-42, 46
Table 2. Details of Studies That Assessed Participants’ Benefit and Harm Expectations of Tests and Screening (continued)
Source
Study Purpose/
Method of Data Collection Participants
Outcomes and/or Measures Relevant
to Systematic Review Purpose Authors’ Conclusions
Haggstrom and
Schapira,41
2006
To assess racial
differences in perception
of risk of breast cancer
survival and screening
mammography benefit/
Written survey completed
in person at the clinic
254 (18% response rate)
women 40-85 y (mean, 55 y)
randomly sampled from
2 general internal medicine
academic clinics in the US.
Excluded if breast cancer
history, dementia, or <2 y life
expectancy
For women your age, how much do you think
regular mammograms decrease the risk of dying
from breast cancer? (5 response options: not at all,
5%-25%, 26%-50%, 51%-75%, 76%-100%)
Awareness of risk
perceptions can help
physicians tailor patient
education
Lewis et al,42
2003
To assess effect of
providing information
about mammography
benefits and harms on
screening perception/
Survey completed face to
face at clinic (prior to
receiving intervention)
(only baseline data
reported here)
Convenience sample (55%
response rate) of 179 women
aged 35-49 y from a general
internal medicine academic
clinic in the US (excluded if
breast cancer history or unable
to read and write English)
Out of 1000 women who have yearly
mammograms for 10 y, how many
1. live longer because of screening?
2. would have a false positive?
3. would be upset by a false positive even after
they knew there was nothing wrong? (response
options not clearly specified)
Women strongly perceived
that mammography
benefits outweighed the
harms; and giving
accurate information had
no effect on these
perceptions
Neptune et al,43
1994
To assess baseline
knowledge of risk of IV
contrast material for
diagnostic radiology/
Written survey completed
while at outpatient clinic
147 (98% response rate)
consecutive outpatients, in US,
undergoing CT (n = 109) or
urogram (n = 41) requiring IV
contrast material. 68% had
previous IV contrast radiology,
54% male, 47% >55 y
The chance of (4 response options for each Q)
1. a minor reaction from IV contrast material
2. a serious reaction from the injection of contrast
material
3. dying from the injection of contrast material
Information regarding the
risks of IV contrast
material cannot be
considered common
knowledge among
patients
Philips et al,44
2003
To explore beliefs and
perceptions of cervical
cancer and its screening
among university
students/
Survey sent through
university internal mail
Convenience sample (44%
response rate) of 222 female
students aged 18-23 y (mean,
19 y) attending a university in
the UK
1. How many cases of cervical cancers are
prevented in the UK each year by a cervical
screening program?
2. How accurate is the cervical smear test?
Most participants
overestimated the
incidence of cervical
cancer prevented, had
some inaccurate
knowledge about the
screening program, and
had distorted beliefs
about the power of
screening
Phillips et al,45
2005
To estimate women’s
knowledge of cervical
cancer, risk factors, and
efficacy of screening/
Survey distributed at
general practices for
return by post or to the
practice
1244 (28% response rate)
women eligible for cervical
screening attending for
routine (nonscreening)
consultations with a general
practitioner at 20 practices in
the UK
1. How many cases of cervical cancers are
prevented in the UK each year by a cervical
screening program?
2. How accurate is the cervical smear test?
Women typically
overestimate both the
incidence of cervical
cancer and the efficacy of
screening
Schwartz et al,46
2000
To determine women’s
attitudes to and
knowledge of false-
positive mammography
results and detection of
ductal carcinoma in situ
after screening
mammography/
Mailed survey
479 eligible (65% response
rate) women (18-97 y who did
not report a history of breast
cancer) randomly selected
from telephone directories
in US
Visual analogue scale (Q1, 2):
1. For a 60-year-old woman who has yearly
mammograms for 10 y, what is the chance she will
have a false alarm where one mammogram will
look like she has cancer even when she doesn’t?
2. In a healthy 60-year-old woman who has breast
cancer and no other symptoms, what is the chance
a mammogram will find the cancer?
3. If this woman had yearly mammograms for the
next 10 y, how much would it change her chance of
dying of breast cancer?
Women are aware of false-
positive results and view
them as acceptable
consequences of
screening mammography.
Most are unaware that
screening can detect
cancers that may not
progress
Sin et al,47
2013
To investigate patients’
awareness of radiation
dose and associated risks
of radiological
procedures/
Face-to-face survey,
completed by participants
while at the hospital
173 private and public
patients randomly sampled
(200 patients invited, 87%
response rate) undergoing a
diagnostic radiology procedure
at 1 Hong Kong hospital. Mean
(range) age, 53 (21-83) y;
48% male
1. the risk of inducing a fatal cancer from CT for
adults
2. the amount of radiation you receive from a CT is
equivalent to that received from how many chest
radiographs?
Most patients
underestimated the fatal
cancer risk of CT scanning
and many underestimated
risk of CT compared with
chest radiography. Patient
radiation awareness is
unsatisfactory
Abbreviations: CT, computed tomography; IV, intravenous; PSA, prostate-specific antigen; Q, question; QOL, quality of life; UK, United Kingdom; US, United States.
a Qs also asked for “in the next 20 y,” but results were not provided in the article.
bAlso asked whether they thought there would be pain, radiation, and adverse effects, but quantification of risk was not assessed and data were not eligible.
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ticipantscorrectly responding ranging from2%to77%.For 13 (65%)
of the 20 benefit outcomes that were comparedwith a correct an-
swer, benefitwasoverestimatedbyat least 50%ofparticipants. All
6 harm outcomeswere aboutmammography, with the proportion
of correct responses ranging from 9% to 20%.
Cancer—Treatment and Risk-Reducing Surgery
Studies examined risk-reducing surgery,22,23 stem cell
transplantation,20 and adjuvant chemotherapy for breast cancer.24
One measured benefit and harm expectations20; 3 measured
only benefit expectations. One study22 provided the proportion of
correct responses (33%, 26%), whereas the remainder20,23,24
presented mean estimates of benefit and concluded that
participantsoverestimatedbenefit. For the 1harmoutcome(mortal-
ity related to stem cell transplantation treatment20), the majority
underestimated it.
Cardiovascular Disease—Prevention andManagement
Fivestudies (6outcomes)measuredexpectationsaboutuseofmedi-
cation for preventing cardiovascular disease,18,21,30 coronary
angioplasty,19 or peripheral angioplasty.17 Five outcomes assessed
benefit expectations: for one, 28% responded correctly30; for an-
other, 28% of participants responded correctly and 69%overesti-
matedbenefit18; theother317,19,21 reportedbenefits asmean (orme-
dian)benefit andconcludedthatparticipantsoverestimatedbenefit.
For the 1 harm outcome,19 27% of participants answered correctly
and 55% underestimated the risk of major complications of coro-
nary angioplasty.
Surgery
Inaddition to thecardiovascular surgery studies reported in thesub-
section on cardiovascular disease, 3 studies (10 outcomes) as-
sessed surgery expectations—orthopedic and eye,15 renal
transplant,27 andbariatric surgery.29For the5benefit outcomes, 315
were reported as the proportion of correct responses (25%, 28%,
61%) and 2 asmean estimated benefit,27,29which the authors con-
cludedwere overestimates. For the 5 harmoutcomes,15 correct re-
sponses ranged from13%to56%,withharmunderestimatedby the
majority for 3.
Medication
In addition to themedication studies summarized in other subsec-
tions, 17 outcomes (4 studies)measuredmedication expectations:
infliximab for inflammatorybowel disease,12,26 hormone therapy,14
and medication to prevent hip fracture in osteoporosis.18 Ten out-
comes assessed benefit, with correct response rates ranging from
10% to 34% of participants and at least 50% of participants over-
estimating benefit in 8 outcomes.Of the 7 harmoutcomes, correct
response rates ranged from 2% to 37%, with harm underesti-
mated by at least 50% of participants for 5 outcomes.
Fetal andMaternal Medicine
Ofthe4outcomes(3studies),2measuredbenefitexpectations,with
a low proportion of correct responses: 9% (trial of labor after pre-
viouscesareandelivery13)and8%(fetalabnormalityscan;90%over-
estimatedbenefit of scan32).Of the2harmoutcomes, 38%(trial of
labor13) and 57% of participants (amniocentesis risk37) provided a
correct response.
Diagnostic Radiology Procedures
Expectations weremeasured in 2 studies43,47 with 5 outcomes. All
addressed harm, and correct responses ranged from 18% to 48%,
with authors concluding that many participants underestimated
harms.
Cardiopulmonary Resuscitation
Two studies (3 outcomes) assessed benefit expectations25,48 and
reportedmeanestimatedsuccessrates,withauthorsconcludingthat
participants overestimated the success rate.
Discussion
Toourknowledge, this is thefirst systematic reviewofpatientorpub-
lic expectations of the benefits and harms of medical interven-
tions. Participants rarely had accurate expectations of benefits and
harms, and for many interventions, regardless of whether a treat-
ment, test, or screen, they had a tendency to overestimate its ben-
efits and underestimate its harms.
Strengths of this review include its lack of restrictions on lan-
guageor studydesign, contactwithauthors for additional data, and
diversity in the interventions andcountries included.However, this
diversitymeans that there is sufficient heterogeneity in thewayex-
pectations weremeasured to preclude calculation of summary es-
timates of the size of overestimates and underestimates. For some
studies, we could not calculate the proportion of participants who
providedcorrectanswers,overestimates,orunderestimates. Inoth-
ers, authorsdidnotprovidequantitative information regardingwhat
they considered to be the correct answer yet obviously had an “an-
swer” in mind when drawing conclusions. In studies in which au-
thorsdidprovidea correct estimate,we took their estimates at face
value and did not attempt to verify whether these answers were
based on the best evidence available at the time of that study. In at
least 1 study, trial evidence49 subsequently overturned 1 “correct”
Figure 1. Flow of the Information Through the Phases of the Review
55 Full-text articles excluded
30 Benefit/harm responses not
quantitative
6 Not original research (eg,
commentary)
4 Measured risk of developing
disease
15 Studied effect of giving benefit
and/or harm information and no
usable control group or baseline
data provided
15 252 Records excluded by title
and abstract
36 Articles analyzed
91 Full-text articles assessed for eligibility
15 343 Records screened
14 859 Records identified through
database searching 
484 Additional records identified
through other sources
Patient Expectations of Treatments and Tests Review Clinical Review& Education
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine February 2015 Volume 175, Number 2 281
Downloaded From: http://archinte.jamanetwork.com/ by a UQ Library User  on 10/12/2015
Copyright 2015 American Medical Association. All rights reserved.
answer (hormone therapy is protective against cardiovascular
disease).14Somestudieshadsmall and/or selectivesamples, andthe
measuresused toassessparticipants’ expectationswere largelyun-
tested. The impactonexpectations fromaskingparticipants at vari-
ous stages of intervention consideration (not considering, consid-
ering, already received it) or fromusingvariousmethodsof eliciting
expectations, with some questions asking about personal benefit
and/or harm (eg, what are your chances…) and others about popu-
lation benefit and/or harm (eg, out of 1000 people, how many…),
is not clear.
Figure 2. Proportion of Participants Providing a Correct Estimate, Underestimate, or Overestimate of Intervention Benefit
20100 30 40 50 60 70 9080 100
Participants, %
Schwartz et al,46 2000, decreased breast Ca death by mammography
Phillips et al,45 2005, cervical Ca prevented by screening
Phillips et al,45 2005, accuracy of cervical smear test
Phillips et al,44 2003, cervical Ca prevented by screening
Phillips et al,44 2003, accuracy of cervical smear test
Hudson et al,18 2012, decreased breast Ca death by screening
Hudson et al,18 2012, decreased bowel Ca death by screening
Hoffman et al,16 2010, Ca diagnosis from high PSA
Hoffman et al,16 2010, Ca diagnosis from positive mammogram
Haggstrom and Schapira,41 2006, decreased death risk from breast Ca by mammography
Haakenson et al,40 2006, decreased breast Ca death by mammography
Gigerenzer et al,38 2009, decreased prostate Ca death by PSA screening
Gigerenzer et al,38 2009, decreased breast Ca death by mammography
Domenighetti et al,36 2003, deaths prevented by mammography screening
Domenighetti et al,36 2003, decreased breast Ca death by mammography
Chamot and Perneger,34 2001, decreased breast Ca death by mammography
Barratt et al,31 1999, mammography sensitivity
Cancer screening
Siegel et al,26 2008, IBD remission rate after 1 y of infliximab (parents)
Siegel et al,26 2008, IBD remission after 1 y of infliximab (adults)
Siegel et al,26 2008, IBD improvement with 2 wk of infliximab
Hudson et al,18 2012, hip fractures prevented by medication
Coo et al,14 2001, decreased hip fracture risk from HT in women at higher risk
Coo et al,14 2001, decreased hip fracture risk from HT in healthy women
Coo et al,14 2001, decreased heart disease from HT in women at high risk
Coo et al,14 2001, decreased heart disease from HT in healthy women
Baars et al,12 2009, IBD remission 2 wk from infliximab
Baars et al,12 2009, IBD remission 1 y from infliximab
Medication
Fagerlin et al,15 2010, benefit from back surgery
Fagerlin et al,15 2010, improved vision after cataract surgery
Fagerlin et al,15 2010, pain relief after hip or knee replacement
Surgery
Hudson et al,18 2012, decreased death from cardiovascular disease from medication
Weymiller et al,30 2007, decreased death from cardiovascular disease from statin use
Cardiovascular disease
Bernstein et al,13 2012, success of labor trial after cesarean delivery
Basama et al,32 2004, % fetal abnormalities detected by scan
Fetal and maternal medicine
Mancini et al,22 2006, breast Ca prevented by mastectomy in genetic risk women
Mancini et al,22 2006, ovarian Ca prevented by oophorectomy in genetic risk women
Cancer treatment and risk-reducing surgery
Lewis et al,42 2003, live longer from mammography
Underestimated benefit
Correctly estimated benefit
Overestimated benefit
≥50% of participants overestimated benefit
Ca indicates cancer; HT, hormone therapy; IBD, irritable bowel disease; PSA, prostate-specific antigen.
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Overlyoptimistic interventionexpectationsbypatients and the
publicareundoubtedlycontributing to thegrowingproblemofover-
diagnosis andovertreatment.Thismedicaloptimismhasmany likely
drivers, caused by influences within and beyond the patient-
clinician interaction. The relationship between optimistic bias (in
which individualsperceivethat theyareat less risk thantheirpeers)50
and intervention expectations is not clear. Having unrealistic inter-
vention expectations may enable patients to meet some psycho-
logical needs, such as hope, safety, a sense of control, action, and
reassurance.51 If patients believe that interventions are effective
(which this review suggests that they largely do), they are likely to
request the interventions fromtheir clinicians.52,53Thepointof con-
sultationwith a clinicianpresents anopportunity for education and
correctionofmisperceptions about effectiveness. Yet theseoppor-
tunities may be missed: clinicians are often poor at detecting ex-
pectations specific to the patient visit54 and may avoid asking di-
rect questions about expectations to circumvent confrontation.55
Even once clinicians are aware of patient expectations, managing
themwell can be difficult. A heavy impact of patient expectations
and requests has been described by physicians, with approxi-
mately half of requests fulfilled only because thepatient asked, de-
spite the physicians feeling uncomfortable about some of them.52
In a survey of US physicians, 36% indicated that they would order
unnecessary investigations because of patient expectations.56
Clinicians’ contributions topatients’ overly optimistic expecta-
tions may range from a failure to detect and correct them to con-
tributing (either activelyorbyomission) to their developmentor re-
inforcement. Clinicians themselves may have overly optimistic
expectationsaboutthebenefitsof interventions57,58andpoorknowl-
edgeofharms59andmayoversell interventionswhenoffering them
topatients.60 Interventionsmaybe recommendedwith thebest of
intentions—reflecting a tendency for clinicians to emphasize doing
Figure 3. Proportion of Participants Providing a Correct Estimate, Underestimate, or Overestimate of Intervention Harm
Participants, %
20100 30 40 50 60 70 9080 100
Medication
Siegel et al,26 2008, lymphoma risk from infliximab (parents)
Siegel et al,26 2008, lymphoma risk from infliximab (adults)
Siegel et al,26 2008, death from infliximab adverse effect
Coo et al,14 2001, increased breast Ca risk from HT in healthy women
Coo et al,14 2001, breast Ca risk from HT in higher risk women
Baars et al,12 2009, lymphoma risk from infliximab
Baars et al,12 2009, death risk from infliximab adverse effect
Surgery
Fagerlin et al,15 2010, need glasses after cataract surgery
Fagerlin et al,15 2010, complications from back surgery
Fagerlin et al,15 2010, not better after back surgery
Fagerlin et al,15 2010, need second procedure after cataract surgery
Fagerlin et al,15 2010, complications from hip or knee replacement
Cancer screening
Haakenson et al,40 2006, noncancerous abnormalities after biopsy
Haakenson et al,40 2006, need to return for additional mammogram
Haakenson et al,40 2006, need biopsies after extra mammogram
Lewis et al,42 2003, upset by false positive from mammography
Lewis et al,42 2003, chance of false positive from mammography
Diagnostic radiology
Sin et al,47 2013, risk of fatal Ca from CT scan
Sin et al,47 2013, No. of chest radiographs to equal dose from CT
Neptune et al,43 1994, risk of severe reaction to contrast material
Neptune et al,43 1994, risk of minor reaction to contrast material
Neptune et al,43 1994, risk of death from contrast material
Cardiovascular disease
Kee et al,19 1997, rate of major complications from angiography
Fetal and maternal medicine
Gekas et al,37 1999, % miscarriage induced by amniocentesis
Bernstein et al,13 2012, risk of uterine rupture during vaginal delivery
Underestimated harm
Correctly estimated harm
Overestimated harm
≥50% of participants underestimated harm
Ca indicates cancer; CT, computed tomography; HT, hormone therapy.
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rather than not doing as a habitual response to health threats and
to try anything for distressed patients, however poor the evidence
of effectiveness61 or even after identifying no benefit.58 In the ab-
senceof supportingempirical evidence, clinicians’ decisions topro-
videan interventionmaybeoverinfluencedbyabelief in thepatho-
physiological effectiveness of the intervention’s mechanism of
action.62,63 Alternatively, clinicians may be unaware of the true ef-
fectiveness or benefit-harm trade-off, or there may be other influ-
ences, such as the lack of incentive for discouraging patients from
proceeding with an intervention58 or pecuniary interests, includ-
ing fee-for-service.5,64
The sometimes misleading and inaccurate portrayal of inter-
vention benefit in messages frommany commercial sources (such
as the pharmaceutical industry65), health services (such as cancer
centers66 and screening services67,68), and themedia69-72 also un-
doubtedly contributes to the development of overly optimistic ex-
pectations in patients and clinicians. A contributor to patients’ un-
derestimatesof interventionharmsmaybethe lackofattentiongiven
to communicating them. This is commonplace and widespread—
occurring in themedia,69-72cancercenteradvertisements,66screen-
ing invitations,67,68 and direct-to-consumer prescription
advertising,65 and even by clinicians. In an evaluation of what phy-
sicians in theUnitedStates tell patients about screeningharms,only
9.5% of patients were informed about the possibility of overdiag-
nosisandovertreatmentduringaconversationaboutcancer screen-
ing, yet 80% wanted to be told of these harms before being
screened.59Clinicians’ poor knowledgeof interventionharms is un-
surprising because, compared with benefits, harms are much less
routinely evaluated and reported in both primary research
studies73,74 and, consequently, systematic reviews.75 In this re-
view’s studies, two-thirds assessed only benefit expectations.
Ironically, one of the influencing factors on clinicians’ decisions
to provide interventions (even with limited or no benefit) is pa-
tients’ expectations.52,58,62 In turn, because the requested inter-
ventionsareoftenprovided,patients’assumptionsthat theyareben-
eficialandnecessaryarereinforced.58Breakingthispositivefeedback
loop is crucial. Shareddecisionmaking is a logical process for achiev-
ing this. It is a process inwhich a clinician andpatient jointly partici-
pate inmaking a health decision, having discussed the options and
their benefits and harms and considered the patient’s values, pref-
erences, and circumstances.76 It provides the opportunity for clini-
cians to elicit patients’ expectations and present accurate and bal-
anced information about the benefits and harms of each option.
Evidence-informed discussions can help patients to construct in-
formed preferences.77
Communicating both the benefits and harms of interventions
to patients may play a key role in dampening their enthusiasm for
some interventions. Studies have reported that many participants
indicated that theywould stop, or not commence, screening if they
knew that screening harms were high or outweighed the
benefits.59,78 Decision aids are one tool that can be used to facili-
tate shareddecisionmakingandcommunicationaboutbenefits and
harms; and if they include probability information, they can im-
prove risk perception accuracy. Decision aid use can also some-
times reduce intervention uptake79—for example, following deci-
sion aid use, people are less likely to choosemajor elective surgery
and undergo prostate-specific antigen screening.79
Beyond decision aids, other initiatives may help to provide in-
dividuals with accurate and balanced information. Examples in-
cludetheDrugFactsBox80andtheChoosingWiselycampaign.81The
DrugFacts Box clearly presents thebenefits andharmsof prescrip-
tion drugs and may improve the accuracy of individuals’ expecta-
tions of medication use.82 The Choosing Wisely initiative provides
evidence-based information for thepublic about interventions that
are commonly used yet may be unnecessary or cause harm. It en-
couragescliniciansandpatients todiscuss these interventionssothat
informed decisions can bemade.81
Clinicians can play a major role in facilitating less use of inter-
ventionsbypatients.53 For example, they can invitepatients topar-
ticipate in decisions about interventions—which themajority want
to do83,84—and ensure that they are sufficiently skilled in facilitat-
ing shareddecisionmakingandawareof resources that canassist.76
However, shareddecisionmaking is yet tobecome routine85; there
are many barriers to its widespread implementation, including the
needfor it tobeembedded inclinician training,86workflowsandsys-
tems, and culture.87-89 Shared decision making also provides a
mechanism to overcome the failings of traditional informed con-
sent practices,90 to achieve truly informed consent.
Whereas overly optimistic patient expectations are undoubt-
edly contributing to intervention overuse, operating in the oppo-
site direction is the possibility that overestimation of intervention
benefit may be a contributor to adherence,91 even if this is based
on unfounded optimism. Hence, for interventions needed by pa-
tients on an ongoing basis, communication and decisions need to
strike a delicate balance between providing accurate information
aboutbenefits andharmsandavoidingcompromisingadherence.92
In this situation also, shared decision making, particularly for pa-
tients with chronic illnesses, can assist with achieving agreement
about a treatment plan and consequently adherence.10,93
Conclusions
The importanceof this review’s findings relates to theappetite that
peoplehave formedical interventions.Manywant tohavemoreand
resist having less.53,94Unless this is counteredby accurate andbal-
anced information, it will continue to be a driver formore interven-
tion use than benefits society.
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